News

July 22, 2019

Antibody-Drug Conjugate Shows Efficacy in Heavily Treated Cancers

News

An investigational antibody-drug conjugate made of the HER2-targeting antibody trastuzumab (marketed as Herceptin and others) attached to a kind of chemotherapy compound has demonstrated notable efficacy in heavily treated ... Read more

July 19, 2019

Genomic Analysis Reveals Differences Between Cancer Cell Lines and Human Cancers

News

New research using “big data” helps highlight the differences between breast cancer cell lines and actual patient samples. This could allow researchers to choose models that more accurately reflect ... Read more

July 17, 2019

Trilaciclib-Chemo Combo Extends Lives of Triple-negative Breast Cancer Patients, Preliminary Phase 2 Findings Show

News

Trilaciclib, a treatment that protects the bone marrow from the damaging effects of chemotherapy, significantly extends the lives of women with metastatic triple-negative breast cancer receiving a chemotherapy regimen ... Read more

July 15, 2019July 15, 2019

$20M Gift to Dana-Farber Will Establish Fund for Metastatic Breast Cancer Research

News

The Dana-Farber Cancer Institute will get $20 million to create the Saverin Breast Cancer Research Fund aimed at extending the lives of metastatic breast cancer patients. The gift from ... Read more

July 12, 2019July 12, 2019

Balixafortide-Halaven Combo Seen to Prolong Survival in Advanced Breast Cancer Patients in Phase 1 Trial

News

A combination of Polyphor‘s investigational therapy balixafortide (POL6326) and Eisai‘s Halaven (eribulin) may prolong the survival of women with HER2-negative metastatic breast cancer, a Phase 1 trial shows. The findings ... Read more

July 10, 2019

Obesity Reprograms Immune Cells in Mammary Tissues to Promote Tumor Development, Study Says

News

Obesity in women with triple-negative breast cancer, the most aggressive kind of breast cancer, reprograms immune cells and creates a chronic inflammatory environment that promotes cancer progression and spread, ... Read more

July 8, 2019

Puma Applies to FDA to Extend Nerlynx’s Use to HER2-Positive Metastatic Breast Cancer

News

Puma Biotechnology is seeking to extend the use of its breast cancer medicine Nerlynx (neratinib), in combination with capecitabine, to treat women with HER2-positive breast cancer whose disease has ... Read more

July 3, 2019

CHMP Recommends Tecentriq-Abraxane Combination to Treat Some Triple-negative Breast Cancers in Europe

News

The  Committee for Medicinal Products for Human Use (CHMP),  an arm of the  European Medicines Agency , has recommended the approval of Tecentriq (atezolizumab) in combination with the chemotherapy Abraxane (nab-paclitaxel) as ... Read more

July 1, 2019July 1, 2019

Fujifilm Bus Hits the Road to Offer Breast Cancer Screenings and Promote Early Diagnosis

News

Fujifilm Medical Systems USA has launched a nationwide effort to enhance access to breast cancer screening and raise awareness about the importance of early disease detection. Called “Aspire to ... Read more

June 28, 2019

Breast Cancer Index Identifies Patients Who Will Benefit From Extended Endocrine Therapy, Data Shows

News

Biotheranostics‘ Breast Cancer Index can help distinguish which breast cancer patients will derive a benefit from prolonged endocrine therapy — allowing those who don’t to stop treatment and avoid ... Read more

Pin It on Pinterest